|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
 |
 |
|
 |
|
|
|
|
|
||||||||||||||||
| ORSP Home | News | Proposal | Funding | PI Guide | Policies | Forms | Compliance | Int.Prop. | |||||||||||||||||||||
| Institutional Biosafety Committee (IBC) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORSP Main > Research Compliance > Institutional Biosafety Committee (IBC) | |||||||||||||||||||||
Institutional
Review Board (IRB) · Institutional Animal
Care and Use Committee (IACUC) Institutional Biosafety Committee (IBC) · University Radiation Safety Committee (URSC) Research Integrity · Conflict of Interest |
|||||||||||||||||||||
| Dr. Paul Klerks, Chair Phone: (337) 482-6356 Email: klerks@louisiana.edu The IBC provides guidance to University researchers who use biological agents or recombinant DNA within the scope of their work. The mission of the IBC is to ensure that research involving biological agents is conducted within existing Federal and State laws and guidelines that aim to protect the safety of workers, the general public, and the environment. |
|||||||||||||||||||||
| Guidelines for Submission and Review of IBC Applications
(Approved 8/28/07) 1.) IBC applications should be submitted for review at least two weeks prior to the regularly scheduled IBC meeting date (typically last week of each month). Information on specific meeting dates will be provided by the IBC chair upon request. 2.) The PI of an application undergoing full review is encouraged to attend the IBC meeting in which their application is being reviewed. The PI will be asked to present a short overview of the project and answer any questions that IBC members may have. The PIs attendance will greatly reduce the chances that specific issues or uncertainties will result in the review being tabled till the next meeting (which would delay the start of their project). 3.) IBC members who notice problems with the application or would like clarifications concerning specific issues will generally direct those to the IBC Chair no less than 5 working days prior to the scheduled meeting. The Chair will forward those to the PI of the application. If the PI is unable to clarify the issue to the satisfaction of the IBC member, the PI will be asked to attend the IBC meeting for an explanation of the issue(s). 4.) In the event that clarifications are not resolved prior to the IBC meeting or when additional questions arise at the IBC meeting that remain unresolved, the application will be "tabled" until clarifications are obtained. If the issue is relatively minor, IBC members may approve a motion that the application will be approved pending clarification of the issue in question (noted in the minutes) in consultation between the Chair and the PI and resolved to the satisfaction of the IBC member(s) who raised the issue(s). 5.) If important issues remain unresolved during the full review, the application will be tabled and will be revisited at the following IBC meeting. The PI will be informed of the "pending" status of the application and would be encouraged to attend the subsequent IBC meeting, in order to explain the issues and/or the application in general. |
|||||||||||||||||||||
| IBC Policies and Procedures PDF Application for Review DOC Change/Renewal Form DOC Biosafety in Microbiological and Biomedical Laboratories PDF Recombinant DNA Regulations LINK NIH Office of Biotechnology Activities LINK |
|||||||||||||||||||||
|
|
|
 |
|
|
|
|
 |
|
Document last revised Wednesday, July 29, 2009 12:32 PM
© Copyright 2006 by the University
of Louisiana at Lafayette
Research & Sponsored Programs, PO Box 43610, Lafayette LA 70504
Phone: 337-482-5811 · Martin Hall, Room 338 · E-Mail: ORSP@louisiana.edu
